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Introduction
Cancer is a disease caused by uncontrolled cell
proliferation that spreads to and damages
surrounding body tissues

Triple Negative Breast Cancer (TNBC) is an
aggressive subtype of breast cancer that often has
worse prognosis (outcome). It is characterized by its
lack of three markers..

What is GD2?
GD2 is a disialoganglioside (glycolipid) found on
the cell surface of TNBC cells

They have a role in cell adhesion, migration, and
cell signaling.

Abstract abstracted
-

A fraction of cells in TNBC are thought to have stem-cell like properties. They are called Breast
cancer stem-like cells (BCSCs)

-

The BCSCs in primary TNBC are responsible for metastasis (spread of tumor from its primary
origin to a different tissue) and chemotherapy resistance

-

This article shows that GD2 is highly expressed in the BCSC population and targeting them can
be an effective way to inhibit breast cancer growth and metastasis

Method
The researchers conducted a series of experiments
but I summarized the most important ones that lead to
the conclusion

-Immunohistochemistry of frozen primary tumor
tissues
- Effect of dinutuximab (anti GD2 chemotherapy) on
TNBC patient-derived xenograft growth

Immunohistochemistry of frozen primary tumor tissues
Goal is to analyze GD2 expression in TNBC
Steps:
1- TNBC tissue was obtained and sectioned 7-10 μm in thickness using a cryotone
2- A series of fixative chemicals were added to preserve and maintain the tissue
3- The slides were incubated with an anti-GD2 primary antibody for an hour
4- The tissue was then stained with DAB and hematoxylin to enhance tissue contrast allowing us to analyze the
slide under a microscope

Effect of dinutuximab (anti GD2 chemotherapy) on in vivo tumor growth in a TNBC cell line xenograft
model
Goal is to determine whether dinutuximab is effective in killing TNBC cells and shrinking
tumor

Results

GD2 is upregulated in TNBC cell lines, PDX (patient derived xenograft) models and TNBC tissues

Figure A compares GD2 expression in normal breast tissue
and tumor tissue in immunohistochemical analysis. Black
arrows indicate GD2 staining.

Figure D compares GD2 expression in tumor
tissue and adjacent normal tissue. We can see a
significant increase in expression in tumor tissue

Results

-Results from the dinutuximab vs. rituximab
(control) treatment in TNBC xenograft model

-Results clearly show that dinutuximab is a
significantly effective treatment in TNBC

Conclusion
-The study demonstrated that GD2 is a
therapeutic target in TNBC
-The chemotherapeutic agent
dinutuximab targets GD2+ cells and
inhibits cell adhesion, migration, and
mammosphere formation by regulating
the mTOR pathway involved in cell
proliferation and migration
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Discussion Questions
1- Sometimes in cancer, we do not know the exact reason behind tumor initiation and progression. Do
you think that we should spend our time researching the details of cancer and its development or to
develop treatments even when we do not know how the treatments work and if they will work in
different patients?
2- Do you see a potential in understanding and targeting cancer stem cells ?
3- Do you have any thoughts or concerns or see any limitations in today’s approach to cancer research?

